VACCINATION AGAINST SWINE FLU CAUSED NARCOLEPSY IN SEVERAL EUROPEAN COUNTRIES

Show full item record



Permalink

http://hdl.handle.net/10138/340624

Citation

Boström , I , Lindberger , O , Partinen , M & Landtblom , A M 2020 , ' VACCINATION AGAINST SWINE FLU CAUSED NARCOLEPSY IN SEVERAL EUROPEAN COUNTRIES ' , Health Risk Analysis = Analiz riska zdorovʹû , vol. 2020 , no. 3 , pp. 180-185 . https://doi.org/10.21668/health.risk/2020.3.22.eng

Title: VACCINATION AGAINST SWINE FLU CAUSED NARCOLEPSY IN SEVERAL EUROPEAN COUNTRIES
Author: Boström, I.; Lindberger, O.; Partinen, M.; Landtblom, A. M.
Contributor organization: Department of Neurosciences
HUS Neurocenter
University of Helsinki
Date: 2020-09-30
Language: eng
Number of pages: 6
Belongs to series: Health Risk Analysis = Analiz riska zdorovʹû
ISSN: 2542-2308
DOI: https://doi.org/10.21668/health.risk/2020.3.22.eng
URI: http://hdl.handle.net/10138/340624
Abstract: Narcolepsy is a rare sleeping disorder that gives sleep onset rapid eye movement periods and excessive daytime sleepiness. It is divided into two subgroups, narcolepsy type 1 where there also is orexin deficiency and cataplexy and narcolepsy type 2 that lack these features. Narcolepsy type 1 is assumed to be an autoimmune disease with destruction of orexin-producing cells. The pathology behind is unclear. There is a strong association to a class II HLA allele, HLADQB1*06:02 and the H1N1-virus and streptococcal infections has also been associated with narcolepsy. The severity of narcolepsy differs between patients from those who can manage their disease without medication to those who has a severe impact on their everyday life. There is a diagnostic delay between the onset of symptoms and time for diagnosis that in some cases can be more than a decade. The global mean prevalence is 30 per 100 000 inhabitants. The incidence in children in northern Europe has risen since 2010. An early study of the 2009 H1N1 influenza A pandemic indicated a high mortality and prompted efforts to rapidly come up with a vaccine. One of these was Pandemrix that was the most widely used in Europe and 61 % of the inhabitants in Sweden was vaccinated. Studies have shown an increased incidence of narcolepsy type 1 in European countries that had used Pandemrix, but no increased risk was seen in countries that had used other vaccines than Pandemrix.
Description: Publisher Copyright: © 2020 Boström I., Lindberger O., Partinen M., Landtblom A.M. All Rights Reserved.
Subject: diagnostic delay
H1N1-virus
incidence
narcolepsy
Pandemrix
prevalence
3112 Neurosciences
Peer reviewed: Yes
Rights: cc_by_nc
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
health_risk_analysis_2020_3_22.pdf 194.5Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record